SAN CLEMENTE, Calif., Oct. 4, 2017 — ROX Medical, Inc., a privately held medical device company pioneering an innovative interventional vascular therapy for Uncontrolled Hypertension, announced today that the first patient was treated in the CONTROL HyperTeNsion (HTN)-2 clinical study, the Company's pivotal study to evaluate the safety and effectiveness of the ROX Coupler used to create an arterio-venous anastomosis in the iliac vessels, in patients with high blood pressure.

More than half a million people were diagnosed with obesity-related cancers in the U.S. in 2014, the CDC reported Tuesday, and those numbers aren’t expected to deflate anytime soon.

A new study comparing vegetable oils suggests an essential fatty acid has a stronger tie to weight gain than saturated fat intake.

It’s time to turn up the heat—scientists in Finland have released evidence that frequent sauna bathing can decrease risk factors for men diagnosed with hypertension.

PLAINSBORO, N.J., Sept. 29, 2017 — Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) approved Fiasp® (insulin aspart injection) 100 Units/mL, a fast-acting mealtime insulin indicated to improve glycemic control in adults with type 1 and type 2 diabetes.

Severely obese patients who underwent gastric bypass surgery showed favorable outcomes more than a decade later, including weight loss and remission of type 2 diabetes, a study published in the New England Journal of Medicine states.

The FDA has approved Abbott’s FreeStyle Libre Flash Glucose Monitoring System, the first personal continuous glucose monitor that doesn’t require finger stick calibration.

Knowledge and treatment of hypertension in susceptible patients might be expanding in the U.S. and other developed countries, but research has shown that trend doesn’t translate across socioeconomic borders.